{"id":"standard-of-care-endocrine-treatment","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Hot flashes"},{"rate":"30-50%","effect":"Musculoskeletal pain"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by binding to estrogen receptors on cancer cells, thereby inhibiting the growth and proliferation of these cells. This is particularly effective in hormone receptor-positive breast cancer.","oneSentence":"Blocks estrogen receptors to prevent cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:22.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT04615988","phase":"","title":"Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-06-09","conditions":"Thyroid, PD-1, Cancer","enrollment":17},{"nctId":"NCT07361874","phase":"NA","title":"IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-05","conditions":"Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's","enrollment":75},{"nctId":"NCT06869057","phase":"NA","title":"Re-Engineered Discharge for Diabetes Care Transitions","status":"NOT_YET_RECRUITING","sponsor":"University of Massachusetts, Worcester","startDate":"2026-05-01","conditions":"Diabetes Mellitus Type 2, Social Determinants of Health (SDOH), Hospital Readmission","enrollment":412},{"nctId":"NCT07106632","phase":"PHASE3","title":"Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04-01","conditions":"Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer","enrollment":3380},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT06016738","phase":"PHASE3","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2023-11-16","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":510},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05639556","phase":"","title":"Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2023-04-20","conditions":"Cystic Fibrosis","enrollment":300},{"nctId":"NCT07470580","phase":"NA","title":"Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-04-01","conditions":"Primary Aldosteronism Due to Conn Adenoma, Radiofrequency Ablation Treatment, Adrenalectomy","enrollment":134},{"nctId":"NCT07466875","phase":"NA","title":"Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients","status":"NOT_YET_RECRUITING","sponsor":"Chiao-Chiao Liao","startDate":"2026-04-01","conditions":"Nicotine Dependence, Nicotine Withdrawal, Tobacco Use Disorder","enrollment":60},{"nctId":"NCT04604613","phase":"","title":"Prediction of Recurrence Among Low Risk Endometrial Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-11-08","conditions":"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","enrollment":518},{"nctId":"NCT05700006","phase":"","title":"Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-07-25","conditions":"Breast Neoplasm Female, Arthralgia, Aging","enrollment":94},{"nctId":"NCT06671912","phase":"PHASE3","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-19","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1156},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT07281833","phase":"PHASE3","title":"Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment","status":"RECRUITING","sponsor":"West German Study Group","startDate":"2025-11-27","conditions":"Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer","enrollment":250},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07432178","phase":"PHASE3","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-23","conditions":"Breast Cancer","enrollment":2288},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT06471322","phase":"NA","title":"A Multi-Disciplinary Technology-Based Care for Diabetic Ketoacidosis in Patients With Type 1 Diabetes","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2024-11-15","conditions":"Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT05785832","phase":"NA","title":"A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tandem Diabetes Care, Inc.","startDate":"2023-06-01","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":319},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT07409948","phase":"NA","title":"Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms","status":"NOT_YET_RECRUITING","sponsor":"Addis Ababa University","startDate":"2026-03-15","conditions":"Breast Neoplasms, Musculoskeletal Pain, Arthralgia","enrollment":88},{"nctId":"NCT07410637","phase":"NA","title":"Impact of Thyroid Hormones on Human Glucose and Energy Metabolism","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2026-02-04","conditions":"Graves Disease, Thyroid Cancer","enrollment":60},{"nctId":"NCT06517212","phase":"PHASE2","title":"Tirzepatide Weight Loss for MRD+ Early Breast Cancer","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2024-11-26","conditions":"Breast Cancer, Breast Neoplasms, Breast Cancers","enrollment":48},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT05944432","phase":"NA","title":"CGM Use in Adults With Type 2 Diabetes on Basal Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Diabetes Care","startDate":"2023-07-14","conditions":"Diabetes Mellitus, Type 2","enrollment":470},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT07242118","phase":"NA","title":"Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-11-04","conditions":"Breast Cancer Female","enrollment":18},{"nctId":"NCT04923542","phase":"PHASE1, PHASE2","title":"Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-30","conditions":"Brain Metastases, HR+ Metastatic Breast Cancer","enrollment":31},{"nctId":"NCT06388122","phase":"","title":"DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-30","conditions":"HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT06203067","phase":"NA","title":"Type 1 Together: A Peer Mentorship Program to Bolster Use of CGM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nemours Children's Clinic","startDate":"2024-04-19","conditions":"Diabetes Mellitus, Type 1","enrollment":37},{"nctId":"NCT04054557","phase":"NA","title":"Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2019-07-31","conditions":"Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7","enrollment":305},{"nctId":"NCT01796197","phase":"PHASE2","title":"Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-08","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":"Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer","enrollment":297},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04134260","phase":"PHASE3","title":"Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2020-04-16","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8","enrollment":586},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT06624462","phase":"NA","title":"Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2023-10-10","conditions":"Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication","enrollment":84},{"nctId":"NCT04968964","phase":"NA","title":"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-03-07","conditions":"Breast Cancer, Cancer of the Breast","enrollment":55},{"nctId":"NCT04762979","phase":"PHASE2","title":"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marina N Sharifi","startDate":"2021-02-12","conditions":"Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer","enrollment":44},{"nctId":"NCT06769906","phase":"NA","title":"Effectiveness of Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2025-01-09","conditions":"Diabetes Mellitus Type 2, Continuous Glucose Measurement, Depressive Symptom","enrollment":46},{"nctId":"NCT07214532","phase":"NA","title":"Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Natera, Inc.","startDate":"2026-03","conditions":"Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)","enrollment":725},{"nctId":"NCT07243002","phase":"","title":"Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":3000},{"nctId":"NCT05754528","phase":"PHASE4","title":"Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-07-28","conditions":"Breast Cancer","enrollment":240},{"nctId":"NCT00929214","phase":"PHASE2","title":"Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-24","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT01723774","phase":"PHASE2","title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-10","conditions":"Breast Neoplasms","enrollment":84},{"nctId":"NCT06314061","phase":"PHASE4","title":"The Effect of Continuous Glucose Monitoring in Surgical Patients With Diabetes.","status":"RECRUITING","sponsor":"Christian S. Meyhoff","startDate":"2024-06-24","conditions":"Diabetes Mellitus, Dysglycemia, Perioperative Complication","enrollment":200},{"nctId":"NCT02530177","phase":"","title":"Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-08-19","conditions":"Non-Metastatic Breast Cancer","enrollment":546},{"nctId":"NCT06297850","phase":"","title":"Accuracy of Continuous Glucose Monitoring in Patients With Diabetes. A Prospective Observational Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2024-04-01","conditions":"Diabetes Mellitus, Dysglycemia, Perioperative Complication","enrollment":60},{"nctId":"NCT06488469","phase":"NA","title":"Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2026-07-01","conditions":"Type 1 Diabetes","enrollment":50},{"nctId":"NCT06781996","phase":"PHASE3","title":"A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":180},{"nctId":"NCT07242352","phase":"PHASE3","title":"Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":1520},{"nctId":"NCT04565054","phase":"PHASE3","title":"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2020-09-02","conditions":"Breast Cancer Female","enrollment":1260},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT04543799","phase":"","title":"Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer","status":"RECRUITING","sponsor":"Oncology Institute of Southern Switzerland","startDate":"2020-09-24","conditions":"Prostate Cancer, Breast Cancer","enrollment":60},{"nctId":"NCT06418880","phase":"PHASE3","title":"Automated Insulin Delivery for Inpatients With Dysglycemia","status":"COMPLETED","sponsor":"Emory University","startDate":"2025-01-22","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":130},{"nctId":"NCT05120544","phase":"NA","title":"Expanding Technology-Enabled Nurse Delivered Chronic Disease Care","status":"COMPLETED","sponsor":"Duke University","startDate":"2022-04-21","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":220},{"nctId":"NCT07091864","phase":"NA","title":"Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-29","conditions":"Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma","enrollment":116},{"nctId":"NCT07045298","phase":"NA","title":"CGM Use in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Heart Failure, Diabetes Mellitus","enrollment":140},{"nctId":"NCT07198724","phase":"PHASE1, PHASE2","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sarah Sammons, MD","startDate":"2026-03","conditions":"Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer","enrollment":65},{"nctId":"NCT06361940","phase":"PHASE2","title":"Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-09-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT05845021","phase":"NA","title":"Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-27","conditions":"Osteoporosis, Arthroplasty Complications, Fragility Fracture","enrollment":2000},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT06645873","phase":"NA","title":"Exploration of Continuous Glucose Monitoring on the Intensive Care Unit","status":"COMPLETED","sponsor":"Kim Kamphorst","startDate":"2024-12-17","conditions":"Hypoglycemia, Hyperglycemia","enrollment":100},{"nctId":"NCT04264572","phase":"NA","title":"Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-01-21","conditions":"Diabetes Mellitus, Type 2","enrollment":600},{"nctId":"NCT02889874","phase":"NA","title":"EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Breast Cancer Trials, Australia and New Zealand","startDate":"2017-08-21","conditions":"Early Stage Breast Carcinoma","enrollment":1167},{"nctId":"NCT05919108","phase":"PHASE2","title":"Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2024-05-30","conditions":"Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer","enrollment":30},{"nctId":"NCT06741189","phase":"NA","title":"Cardiopediatric Home Monitoring Tool","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-09-11","conditions":"Congenital Heart Defect","enrollment":186},{"nctId":"NCT04379570","phase":"PHASE3","title":"Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-02-15","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":1167},{"nctId":"NCT06154915","phase":"","title":"Immune Cells in Diabetic Chronic Foot Ulcers","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2022-09-09","conditions":"Diabetic Foot, Immune Defect","enrollment":40},{"nctId":"NCT04055493","phase":"PHASE3","title":"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2019-07-02","conditions":"Breast Cancer Female","enrollment":1684},{"nctId":"NCT06512350","phase":"","title":"Identifying Patterns in the Breath of Individuals With Breast Cancer","status":"RECRUITING","sponsor":"Breathe BioMedical Inc","startDate":"2025-02-25","conditions":"Breast Cancer","enrollment":1000},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT07088549","phase":"NA","title":"Intermittent Versus Continuous Glucose Monitoring in Intensive Care Unit","status":"NOT_YET_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-07","conditions":"Critical Illness, Hyperglycaemia, Hypoglycaemia","enrollment":200},{"nctId":"NCT04352777","phase":"PHASE2","title":"Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor","enrollment":18},{"nctId":"NCT06457139","phase":"NA","title":"Preventing T2DM After GDM With Immediate Postpartum Screening","status":"RECRUITING","sponsor":"University of Massachusetts, Worcester","startDate":"2025-06-01","conditions":"Gestational Diabetes, Type 2 Diabetes","enrollment":116},{"nctId":"NCT05837455","phase":"PHASE2","title":"NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-30","conditions":"Breast Cancer, Cancer of the Breast","enrollment":81},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT04767594","phase":"","title":"First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-10-27","conditions":"Breast Neoplasms","enrollment":1409},{"nctId":"NCT06569589","phase":"","title":"Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat","status":"RECRUITING","sponsor":"Jens Titze","startDate":"2023-12-27","conditions":"Hypertension, Primary Aldosteronism, Hypokalemia","enrollment":80},{"nctId":"NCT06934681","phase":"NA","title":"Exercise to Fight Obesity","status":"RECRUITING","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2025-05-19","conditions":"Morbid Obesity, Bariatric Surgery, Telerehabilitation","enrollment":72},{"nctId":"NCT05584410","phase":"NA","title":"Digitalization of Osteoarthritis Care","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-12-05","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":315},{"nctId":"NCT06989450","phase":"NA","title":"Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer","status":"RECRUITING","sponsor":"Sidekick Health","startDate":"2025-05-31","conditions":"Breast Cancer, Cancer","enrollment":140},{"nctId":"NCT05737745","phase":"NA","title":"FitEx for Endometrial Cancer Survivors: Initial Efficacy","status":"COMPLETED","sponsor":"Carilion Clinic","startDate":"2023-02-01","conditions":"Endometrial Cancer, Obesity, Sedentary Behavior","enrollment":111},{"nctId":"NCT06957379","phase":"PHASE2","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-29","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT03219476","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-02-05","conditions":"Breast Cancer, Invasive Breast Cancer","enrollment":37},{"nctId":"NCT03155997","phase":"PHASE3","title":"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2017-07-12","conditions":"Breast Cancer","enrollment":5637},{"nctId":"NCT06932497","phase":"","title":"Gemelli Longitudinal Cohort on Long-term Outcomes in RheumatIc diseAses","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-04-07","conditions":"Rheumatic Disease","enrollment":5000},{"nctId":"NCT02204098","phase":"PHASE1","title":"Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-01-07","conditions":"Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast","enrollment":27},{"nctId":"NCT05442853","phase":"NA","title":"Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients","status":"COMPLETED","sponsor":"Malcom Randall VA Medical Center","startDate":"2023-04-01","conditions":"Hyperglycemia, Hypoglycemia, Critical Illness","enrollment":85},{"nctId":"NCT05568472","phase":"NA","title":"Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-03-29","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":565},{"nctId":"NCT04663061","phase":"NA","title":"Diabetes Data-Assisted Remission Trial (DDART)","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-06-09","conditions":"Type 2 Diabetes, Obesity","enrollment":65},{"nctId":"NCT06681428","phase":"NA","title":"Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers","status":"RECRUITING","sponsor":"Tides Medical","startDate":"2024-11-14","conditions":"Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers","enrollment":240},{"nctId":"NCT02446405","phase":"PHASE3","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":1125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard-of-care endocrine treatment","genericName":"Standard-of-care endocrine treatment","companyName":"West German Study Group","companyId":"west-german-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks estrogen receptors to prevent cancer cell growth. Used for Hormone receptor-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}